News Releases

<< Back
Prestige Brands Holdings, Inc. Reports Record Second Quarter Fiscal 2016 Revenues Up 13.7% to $206.1 Million

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Nov. 5, 2015-- Prestige Brands Holdings, Inc. (NYSE-PBH) today announced results for the second quarter and first six months of fiscal year 2016, which ended September 30, 2015, and updated the outlook previously provided.

Financial highlights for the second quarter and first six months of fiscal year 2016 include:

  • Second quarter revenues increased 13.7% over the prior year period to a record $206.1 million, including the impact of foreign currency fluctuations;
  • Free cash flow of $46.2 million for the quarter increased 26.4% above prior year period;
  • Adjusted EBITDA for the quarter was $75.6 million, an increase of 19.6% over the prior year period;
  • Earnings per share for the quarter were $0.60, 20.0% above prior year period.
  • Fiscal first half year revenues were $398.2 million, up 21.8% over the prior year period including the impact of foreign currency fluctuations and in line with outlook previously provided.

Second Quarter and First Half of Fiscal 2016 Ended September 30, 2015

Reported revenues for the second quarter of fiscal 2016 were $206.1 million, an increase of 13.7% over the prior year comparable quarter’s revenues of $181.3 million. Reported revenues for the six month period ended September 30, 2015 totaled $398.2 million, an increase of 21.8% over the prior year comparable six month period’s revenues of $327.0 million. Foreign currency fluctuations negatively impacted reported revenues for both the fiscal second quarter and six month periods by $5.3 million and $8.0 million, respectively.

The results of both the fiscal second quarter and six month periods reflect continued strong consumption levels across the Company’s core over-the-counter (OTC) healthcare brands, continued growth in the international business, as well as contributions from the acquisitions of Insight Pharmaceuticals (Insight) and Hydralyte.

Net income for the second quarter of fiscal 2016 totaled $31.8 million, an increase of (i) 20.6% over the prior year comparable quarter’s adjusted net income of $26.4 million and (ii) an increase of 93.2% over the prior year comparable quarter’s reported net income of $16.5 million. Earnings per share for the second quarter of fiscal 2016 were $0.60, an increase of (i) 20.0% over the prior year’s adjusted earnings per share of $0.50 which, excluded acquisition and transition items related to Insight and Hydralyte, and (ii) 93.5% over the prior year’s reported earnings per share of $0.31. Net income and earnings per share for the second quarter of fiscal 2016 did not include any adjustments.

Reported net income for the first six months of fiscal 2016 totaled $58.0 million compared with the prior year comparable period of $33.2 million. Reported earnings per share for the first six month period of fiscal 2016 were $1.09, 73.0% higher than the prior year comparable period’s reported earnings per share of $0.63 per share. Adjusted net income for the first six months of fiscal 2016 increased 23.7% to $59.2 million compared to $47.9 million in the prior year comparable six month period, and excluded items related to the CEO’s retirement, loss on extinguishment of debt and other costs associated with acquisitions. Adjusted earnings per share for the first six month period of fiscal 2016 increased 23.1% to $1.12 from $0.91 in the prior year comparable period and excluded the items described above.

Free Cash Flow, Adjusted EBITDA & Balance Sheet

The Company's free cash flow for the second quarter ended September 30, 2015 was $46.2 million compared to the prior year comparable quarter’s (i) adjusted free cash flow of $36.5 million, an increase of 26.4%, and (ii) free cash flow of $26.5 million, an increase of 74.2%. For the fiscal year to date, free cash flow totaled $88.9 million. Adjusted EBITDA for the second quarter of fiscal 2016 was $75.6 million, an increase of 19.6% over the prior year comparable quarter’s adjusted EBITDA of $63.2 million. For the fiscal year to date, adjusted EBITDA totaled $145.2 million, an increase of 27.1% over the prior year comparable period’s results of $114.3 million.

The Company's net debt at September 30, 2015 was approximately $1.48 billion, reflecting net debt repayments of approximately $45.0 million during the second quarter of fiscal 2016. At September 30, 2015, the Company’s covenant-defined leverage ratio was approximately 5.0.

Segment Review

Reported revenues for the North American OTC Healthcare segment were $163.9 million for the second quarter of fiscal 2016, 19.0% higher than the prior year comparable quarter's revenues of $137.8 million. For the first six months of the current fiscal year, reported revenues for the North American OTC Healthcare segment were $319.6 million, an increase of 28.8% over the prior year comparable period’s revenues of $248.2 million.

Reported revenues for the International OTC Healthcare segment for the second quarter of fiscal 2016 were $17.4 million, 1.5% higher than the prior year comparable period’s results of $17.2 million. For the first six months of the current fiscal year, reported revenues for the International OTC Healthcare segment were $31.6 million, an increase of 2.4% over the prior year comparable period’s revenues of $30.9 million. These results include the impact of foreign currency fluctuations.

Revenues for the Household Cleaning segment were $24.7 million for the second quarter of fiscal 2016, a decrease of 6.2% over the prior year comparable quarter's revenues of $26.3 million. The decrease in revenues is due largely to differences in the timing of promotional programs and new product introductions in the prior year comparable period. For the first six months of the current fiscal year, reported revenues for the Household Cleaning segment were $47.0 million, a decrease of 1.9% over the prior year comparable six month period’s revenues of $47.9 million.

Commentary & Outlook

“We are very pleased with the overall strong performance of both the second quarter and the fiscal year-to-date results, highlighted by record revenues and earnings which were in line with the outlook we provided for both periods,” said Ron Lombardi, President and CEO. “In fact, our second quarter revenues of $206.1 million set the record for our highest revenue-generating quarter in the Company’s history.”

“With core OTC and international growth of 3.0% for the second quarter and 4.8% for the first half of the year, continued favorable consumption trends, and strong marketing and sales initiatives, we believe we are very well-positioned for the balance of the fiscal year,” he said.

“For the full fiscal year ending March 31, 2016, we are updating our outlook for revenues to recognize the slightly higher than anticipated impact of foreign currency fluctuations on our topline. For the second half of the fiscal year, we now expect revenue growth between 0.5% and 1.5% and full year revenue growth of +10% to +11%,” Mr. Lombardi said. “Even though the foreign currency impact is slightly higher than previously expected, we are reaffirming our cash flow and earnings per share outlook. We now anticipate fiscal 2016 adjusted earnings per share growth to be at the high end of our previously provided $2.05 to $2.10 range. At this time, we do not expect foreign currency fluctuations to affect the Company’s earnings per share or free cash flow for the balance of the fiscal year.”

Mr. Lombardi continued, “The Company’s industry-leading free cash flow was a record $89 million for the first six months of the fiscal year, more than half way toward the full fiscal year outlook. We are reconfirming the free cash flow outlook previously provided of $175 million or more. These record levels of free cash flow enable the Company to continue to rapidly de-lever, build M&A capacity, increase marketing spend and invest in innovation and brand building as we position our company for long-term success,” he said.

Q2 Conference Call & Accompanying Slide Presentation

The Company will host a conference call to review its second quarter results on November 5, 2015 at 8:30 am EDT. The toll-free dial-in numbers are 877-784-9650 within North America and 530-379-4717 outside of North America. The Company will provide a live Internet webcast, a slide presentation to accompany the call, as well as an archived replay, all of which can be accessed from the Investor Relations page of the Company's website at http://prestigebrands.com. The slide presentation can be accessed just before the call from the Investor Relations page of the website by clicking on Webcasts and Presentations. Telephonic replays will be available for two weeks following the completion of the call and can be accessed at 855-859-2056 within North America and at 404-537-3406 from outside North America.

Non-GAAP Financial Information

In addition to financial results reported in accordance with generally accepted accounting principles (GAAP), we have provided certain non-GAAP financial information in this release to aid investors in understanding the Company's performance. Each non-GAAP financial measure is defined and reconciled to its most closely related GAAP financial measure in the “About Non-GAAP Financial Measures” section at the end of this earnings release.

About Prestige Brands Holdings, Inc.

The Company markets and distributes brand name over-the-counter healthcare and household cleaning products throughout the U.S., Canada, and Australia and in certain other international markets. Core brands include Monistat® women’s health products, Nix® lice treatment, Chloraseptic® sore throat treatments, Clear Eyes® eye care products, Compound W® wart treatments, The Doctor's® NightGuard® dental protector, Little Remedies® pediatric products, Efferdent® denture care products, Luden's® throat drops, Dramamine® motion sickness treatment, BC® and Goody's® pain relievers, Beano® gas prevention, Debrox® earwax remover, and Gaviscon® antacid in Canada. Visit the Company's website at www.prestigebrands.com.

Note Regarding Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the federal securities laws that are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" generally can be identified by the use of forward-looking terminology such as "assumptions," "target," "guidance," “strategy,” "outlook," "plans," "projection," "may," "will," "would," "expect," "intend," "estimate," "anticipate," "believe”, "potential," or “continue" (or the negative or other derivatives of each of these terms) or similar terminology. "Forward-looking statements" in this release include, without limitation, statements regarding the Company's expectations regarding future operating results including revenues, adjusted earnings per share and free cash flow, the impact of foreign currency fluctuations, the strength of consumption of the Company's products, the growth of the Company's international business and the Company's expectations of rapid de-levering, building M&A capacity, increasing marketing spend, and investing in innovation and brand building. These statements are based on management's estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those expected as a result of a variety of factors, including the impact of our advertising and promotional initiatives, the severity of the cold and flu season, general economic and business conditions, regulatory matters governing our industry, fluctuating foreign exchange rates, consumer trends, competition in our industry, the ability of our third party manufacturers and suppliers to meet demand for our products in a cost effective manner, and introductions of new products. A discussion of other factors that could cause results to vary is included in the Company's Annual Report on Form 10-K for the year ended March 31, 2015, Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, and other periodic reports filed with the Securities and Exchange Commission.

 
Prestige Brands Holdings, Inc.
Consolidated Statements of Income and Comprehensive Income

(Unaudited)

 
       

Three Months Ended
September 30,

     

Six Months Ended
September 30,

(In thousands, except per share data) 2015       2014 2015       2014
Revenues
Net sales $   205,262 $   180,005 $   396,549 $   324,546
Other revenues 803   1,264   1,648   2,425  
Total revenues 206,065 181,269 398,197 326,971
 
Cost of Sales
Cost of sales (exclusive of depreciation shown below) 86,125   78,727   166,021   142,563  
Gross profit 119,940   102,542   232,176   184,408  
 
Operating Expenses
Advertising and promotion 27,893 25,044 54,315 44,140
General and administrative 16,462 27,128 34,051 44,134
Depreciation and amortization 5,687   3,852   11,407   6,813  
Total operating expenses 50,042   56,024   99,773   95,087  
Operating income 69,898   46,518   132,403   89,321  
 
Other (income) expense
Interest income (33 ) (15 ) (60 ) (47 )
Interest expense 20,700 18,208 42,611 32,893
Loss on extinguishment of debt     451    
Total other expense 20,667   18,193   43,002   32,846  
Income before income taxes 49,231 28,325 89,401 56,475
Provision for income taxes 17,428   11,862   31,425   23,280  
Net income $   31,803   $   16,463   $   57,976   $   33,195  
 
Earnings per share:
Basic $   0.60   $   0.32   $   1.10   $   0.64  
Diluted $   0.60   $   0.31   $   1.09   $   0.63  
 
Weighted average shares outstanding:
Basic 52,803   52,088   52,676   52,023  
Diluted 53,151   52,594   53,055   52,564  
 
Comprehensive income, net of tax:
Currency translation adjustments (11,079 ) (10,830 ) (11,484 ) (8,104 )
Total other comprehensive loss (11,079 ) (10,830 ) (11,484 ) (8,104 )
Comprehensive income $   20,724   $   5,633   $   46,492   $   25,091  
 
 
Prestige Brands Holdings, Inc.
Consolidated Balance Sheets

(Unaudited)

 

(In thousands)

Assets

       

September 30,
2015

     

     March 31,
        2015       

Current assets
Cash and cash equivalents $   22,152 $   21,318
Accounts receivable, net 91,340 87,858
Inventories 77,137 74,000
Deferred income tax assets 8,273 8,097
Prepaid expenses and other current assets 6,877   10,434  
Total current assets 205,779 201,707
 
Property and equipment, net 12,920 13,744
Goodwill 289,061 290,651
Intangible assets, net 2,117,669 2,134,700
Other long-term assets 1,462   1,165  
Total Assets $   2,626,891   $   2,641,967  
 
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable $ 41,777 $ 46,115
Accrued interest payable 9,656 11,974
Other accrued liabilities 41,595   40,948  
Total current liabilities 93,028   99,037  
 
Long-term debt
Principal amount 1,503,600 1,593,600
Less unamortized debt costs (31,736 ) (32,327 )
Long-term debt, net 1,471,864   1,561,273  
 
Deferred income tax liabilities 373,764 351,569
Other long-term liabilities 2,480   2,464  
Total Liabilities 1,941,136   2,014,343  
 
 
Stockholders' Equity
Preferred stock - $0.01 par value
Authorized - 5,000 shares
Issued and outstanding - None
Common stock - $0.01 par value
Authorized - 250,000 shares
Issued - 53,053 shares at September 30, 2015 and 52,562 shares at March 31, 2015 530 525
Additional paid-in capital 439,861 426,584
Treasury stock, at cost - 306 shares at September 30, 2015 and 266 shares at March 31, 2015 (5,121 ) (3,478 )
Accumulated other comprehensive loss, net of tax (34,896 ) (23,412 )
Retained earnings 285,381   227,405  
Total Stockholders' Equity 685,755   627,624  
Total Liabilities and Stockholders' Equity $   2,626,891   $   2,641,967  
 
 
Prestige Brands Holdings, Inc.
Consolidated Statements of Cash Flows

(Unaudited)

 
        Six Months Ended September 30,

(In thousands)

     2015     

     

     2014     

Operating Activities
Net income $   57,976 $   33,195
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 11,407 6,815
Deferred income taxes 21,985 11,496
Amortization of debt origination costs 4,055 3,085
Stock-based compensation costs 5,034 3,403
Loss on extinguishment of debt 451
Loss (gain) on sale or disposal of property and equipment (36 ) 56
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable (3,918 ) (8,363 )
Inventories (3,838 ) 7,264
Prepaid expenses and other current assets 3,436 3,114
Accounts payable (4,519 ) (5,647 )
Accrued liabilities (1,443 ) 2,640  
Net cash provided by operating activities 90,590   57,058  
 
Investing Activities
Purchases of property and equipment (1,683 ) (1,380 )
Proceeds from the sale of property and equipment 344
Proceeds from sale of business 18,500
Acquisition of Insight Pharmaceuticals, less cash acquired (749,666 )
Acquisition of the Hydralyte brand   (77,991 )
Net cash used in investing activities (1,339 ) (810,537 )
 
Financing Activities
Term loan borrowings 720,000
Term loan repayments (50,000 ) (25,000 )
Borrowings under revolving credit agreement 15,000 124,600
Repayments under revolving credit agreement (55,000 ) (58,500 )
Payments of debt origination costs (4,211 ) (16,072 )
Proceeds from exercise of stock options 6,398 2,757
Proceeds from restricted stock exercises 544 57
Excess tax benefits from share-based awards 1,850 1,030
Fair value of shares surrendered as payment of tax withholding (2,187 ) (1,660 )
Net cash (used in) provided by financing activities (87,606 ) 747,212  
 
Effects of exchange rate changes on cash and cash equivalents (811 ) (316 )
Increase (decrease) in cash and cash equivalents 834 (6,583 )
Cash and cash equivalents - beginning of period 21,318   28,331  
Cash and cash equivalents - end of period $   22,152   $   21,748  
 
Interest paid $   40,550   $   27,349  
Income taxes paid $   3,707   $   4,716  
 
 

Prestige Brands Holdings, Inc.

Consolidated Statements of Income

Business Segments

(Unaudited)

 
        Three Months Ended September 30, 2015

(In thousands)

North
American
OTC
Healthcare

     

International
OTC
Healthcare

     

Household
Cleaning

      Consolidated
Gross segment revenues $     165,407 $   17,433 $     23,894 $     206,734
Elimination of intersegment revenues (1,472 )     (1,472 )
Third-party segment revenues 163,935 17,433 23,894 205,262
Other revenues 6     797   803  
Total segment revenues 163,941 17,433 24,691 206,065
Cost of sales 61,499   6,092   18,534   86,125  
Gross profit 102,442 11,341 6,157 119,940
Advertising and promotion 24,440   2,777   676   27,893  
Contribution margin $     78,002   $   8,564   $     5,481   92,047
Other operating expenses 22,149  
Operating income 69,898
Other expense 20,667  
Income before income taxes 49,231
Provision for income taxes 17,428  
Net income $     31,803  
 
 
Six Months Ended September 30, 2015

(In thousands)

North
American

OTC
Healthcare

International
OTC
Healthcare

Household
Cleaning

Consolidated
Gross segment revenues $ 321,746 $ 31,642 $ 45,361 $ 398,749
Elimination of intersegment revenues (2,200 )     (2,200 )
Third-party segment revenues 319,546 31,642 45,361 396,549
Other revenues 46     1,602   1,648  
Total segment revenues 319,592 31,642 46,963 398,197
Cost of sales 119,625   11,382   35,014   166,021  
Gross profit 199,967 20,260 11,949 232,176
Advertising and promotion 47,635   5,500   1,180   54,315  
Contribution margin $     152,332   $   14,760   $     10,769   177,861
Other operating expenses 45,458  
Operating income 132,403
Other expense 43,002  
Income before income taxes 89,401
Provision for income taxes 31,425  
Net income $     57,976  
 
         
Three Months Ended September 30, 2014

(In thousands)

North
American
OTC
Healthcare

     

International
OTC
Healthcare

     

Household
Cleaning

     

Consolidated

Gross segment revenues $     138,318 $   17,151 $     25,246 $     180,715
Elimination of intersegment revenues (710 )     (710 )
Third-party segment revenues 137,608 17,151 25,246 180,005
Other revenues 150   23   1,091   1,264  
Total segment revenues 137,758 17,174 26,337 181,269
Cost of sales 52,186   6,601   19,940   78,727  
Gross profit 85,572 10,573 6,397 102,542
Advertising and promotion 21,441   3,036   567   25,044  
Contribution margin $     64,131   $   7,537   $     5,830   77,498
Other operating expenses 30,980  
Operating income 46,518
Other expense 18,193  
Income before income taxes 28,325
Provision for income taxes 11,862  
Net income $     16,463  
 
 
Six Months Ended September 30, 2014

(In thousands)

North
American
OTC
Healthcare

International
OTC
Healthcare

Household
Cleaning

Consolidated
Gross segment revenues $ 249,291 $ 30,843 $ 45,839 $ 325,973
Elimination of intersegment revenues (1,427 )     (1,427 )
Third-party segment revenues 247,864 30,843 45,839 324,546
Other revenues 327   58   2,040   2,425  
Total segment revenues 248,191 30,901 47,879 326,971
Cost of sales 94,526   11,679   36,358   142,563  
Gross profit 153,665 19,222 11,521 184,408
Advertising and promotion 37,794   5,375   971   44,140  
Contribution margin $     115,871   $   13,847   $     10,550   140,268
Other operating expenses 50,947  
Operating income 89,321
Other expense 32,846  
Income before income taxes 56,475
Provision for income taxes 23,280  
Net income $     33,195  
 

About Non-GAAP Financial Measures

We define Non-GAAP Organic Revenues as Total Revenues excluding revenues associated with products acquired or divested in the periods presented. We define Non-GAAP Organic Revenues on a Constant Currency basis as Total Revenues excluding acquisitions and divestitures and the impact of current year foreign exchange rates on total revenues. We define Non-GAAP Total Revenues on a Constant Currency basis as Total Revenues excluding the impact of currency exchange rates on total revenues. We define Non-GAAP Adjusted EBITDA as earnings before interest expense (income), income taxes, depreciation and amortization, certain other legal and professional fees, other acquisition-related costs, and costs associated with our CEO transition. Non-GAAP Adjusted EBITDA Margin is calculated as Non-GAAP Adjusted EBITDA divided by GAAP Total Revenues. We define Non-GAAP Adjusted Gross Margin as Gross Profit before inventory step up charges, and certain other acquisition and integration-related costs. Non-GAAP Adjusted Gross Margin percentage is calculated based on Non-GAAP Adjusted Gross Margin divided by GAAP Total Revenues. We define Non-GAAP Adjusted General and Administrative expenses as General and Administrative expenses minus certain other legal and professional fees, acquisition and other integration costs, and costs associated with our CEO transition. Non-GAAP Adjusted General and Administrative expense percentage is calculated based on Non-GAAP Adjusted General and Administrative expense divided by GAAP Total Revenues. We define Non-GAAP Adjusted Net Income as Net Income before inventory step-up charges, certain other legal and professional fees, other acquisition and integration-related costs, costs associated with our CEO transition, the applicable tax impacts associated with these items and the tax impacts of state tax rate adjustments and other non-deductible items. Non-GAAP Adjusted EPS is calculated based on Non-GAAP Adjusted Net Income, divided by the weighted average number of common and potential common shares outstanding during the period. We define Non-GAAP Free Cash Flow as net cash provided by operating activities less cash paid for capital expenditures. We define Non-GAAP Adjusted Free Cash Flow as net cash provided by operating activities less purchases of property and equipment plus payments associated with acquisitions for integration, transition, and other payments associated with acquisitions. Non-GAAP Organic Revenues, Non-GAAP Organic Revenues on a Constant Currency basis, Non-GAAP Total Revenues on a Constant Currency basis, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin percentage, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense percentage, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS,Non-GAAP Free Cash Flow, and Non-GAAP Adjusted Free Cash Flow may not be comparable to similarly titled measures reported by other companies.

We are presenting Non-GAAP Organic Revenues, Non-GAAP Organic Revenues on a Constant Currency basis, Non-GAAP Total Revenues on a Constant Currency basis, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin percentage, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense percentage, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, Non-GAAP Free Cash Flow, and Non-GAAP Adjusted Free Cash Flow, because they provide additional ways to view our operation when considered with both our GAAP results and the reconciliation to net income and net cash provided by operating activities, respectively, which we believe provides a more complete understanding of our business than could be obtained absent this disclosure. Each of Non-GAAP Organic Revenues, Non-GAAP Organic Revenues on a Constant Currency basis, Non-GAAP Total Revenues on a Constant Currency basis, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin percentage, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense percentage, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, Non-GAAP Free Cash Flow, and Non-GAAP Adjusted Free Cash Flow is presented solely as a supplemental disclosure because (i) we believe it is a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this data useful in assessing shareholder value; and (iii) we use Non-GAAP Organic Revenues, Non-GAAP Organic Revenues on a Constant Currency basis, Non-GAAP Total Revenues on a Constant Currency basis, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin percentage, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense percentage, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, Non-GAAP Free Cash Flow, and Non-GAAP Adjusted Free Cash Flow internally to evaluate the performance of our personnel and also as a benchmark to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP Organic Revenues, Non-GAAP Organic Revenues on a Constant Currency basis, Non-GAAP Total Revenues on a Constant Currency basis, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin percentage, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense percentage, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, Non-GAAP Free Cash Flow, and Non-GAAP Adjusted Free Cash Flow have limitations, and you should not consider these measures in isolation from or as an alternative to GAAP measures such as Total Revenues, General and Administrative expense, Operating income, Net income, and Net cash Flow provided by operating activities, or cash Flow statement data prepared in accordance with GAAP, or as a measure of profitability or liquidity.

The following tables set forth the reconciliation of Non-GAAP Organic Revenues, Non-GAAP Organic Revenues on a Constant Currency basis, Non-GAAP Total Revenues on a Constant Currency basis, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin percentage, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense percentage, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, Non-GAAP Free Cash Flow, Non-GAAP Adjusted Free Cash Flow, all of which are non-GAAP financial measures, to GAAP Gross Profit, GAAP General and Administrative expense, GAAP Net Income, GAAP Diluted EPS and GAAP Net cash provided by operating activities, our most directly comparable financial measures presented in accordance with GAAP.

 

Reconciliation of GAAP Total Revenues to Non-GAAP Organic Revenues and Non-GAAP Organic Revenues on a
Constant Currency basis and related growth percentages:

 
       

Three Months Ended
September 30,

     

Six Months Ended
September 30,

2015       2014 2015       2014
(In thousands)
GAAP Total Revenues $   206,065   $   181,269   $   398,197   $   326,971  

Adjustments:

Hydralyte revenues (1) (1,217 )
Insight revenues (2) (30,992 )   (73,630 )  
Total adjustments (30,992 )   (74,847 )  
Non-GAAP Organic Revenues 175,073   181,269   323,350   326,971  
Organic Revenue Decline (3.4 )% (1.1 )%
Impact of foreign currency exchange rates (3)   (5,302 )   (7,991 )
Non-GAAP Organic Revenues on a constant currency basis $   175,073   $   175,967   $   323,350   $   318,980  
Constant Currency Organic Revenue Growth (Decline) (0.5 )% 1.4 %
 
(1) Revenue adjustments relate to our International OTC Healthcare segment
(2) Revenue adjustments relate to our North American OTC Healthcare segment
(3) Foreign currency exchange rate adjustments relate to all segments
 
 

Reconciliation of GAAP Total Revenues to Non-GAAP Total Revenues on a Constant Currency basis and related growth percentages:

             

Three Months Ended
September 30,

Six Months Ended
September 30,

2015       2014 2015       2014
(In thousands)
GAAP Total Revenues $   206,065 $   181,269 $   398,197 $   326,971
Impact of foreign currency exchange rates (1)   (5,302 )   (7,991 )
Non-GAAP Total Revenues on a constant currency basis $   206,065   $   175,967   $   398,197   $   318,980  
Constant Currency Revenue Growth 17.1 % 24.8 %
 
(1) Foreign currency exchange rate adjustments relate to all segments
 

Reconciliation of GAAP Gross Profit to Non-GAAP Adjusted Gross Margin and related Adjusted Gross Margin percentage:

 
 
       

Three Months Ended
September 30,

      Six Months Ended
September 30,
2015       2014 2015       2014
(In thousands)
GAAP Total Revenues $   206,065   $   181,269   $   398,197   $   326,971  
 
GAAP Gross Profit $   119,940   $   102,542   $   232,176   $   184,408  

Adjustments:

Inventory step-up charges and other costs associated
with the Hydralyte acquisition (1)

116 246

Inventory step-up charges associated with Insight
acquisition (2)

  653     653  
Total adjustments   769     899  
Non-GAAP Adjusted Gross Margin $   119,940   $   103,311   $   232,176   $   185,307  
Non-GAAP Adjusted Gross Margin % 58.2 % 57.0 % 58.3 % 56.7 %
 
(1) Inventory step-up charges and other costs relate to our International OTC Healthcare segment
(2) Inventory step-up charges relate to our North American OTC Healthcare segment
 
 

Reconciliation of GAAP General and Administrative Expense to Non-GAAP Adjusted General and Administrative
Expense and related Non-GAAP Adjusted General and Administrative Expense percentage:

 
       

Three Months Ended
September 30,

     

Six Months Ended
September 30,

2015       2014 2015       2014
(In thousands)
GAAP General and Administrative Expense $   16,462   $   27,128   $   34,051   $   44,134  

Adjustments:

Costs associated with CEO transition 1,406
Legal and professional fees associated with acquisitions 8,058 9,857
Stamp/Duty Tax on Australian acquisition 2,940
Integration, transition and other costs associated with acquisitions   4,021     4,432  
Total adjustments   12,079   1,406   17,229  
Non-GAAP Adjusted General and Administrative Expense $   16,462   $   15,049   $   32,645   $   26,905  
Non-GAAP Adjusted General and Administrative Expense Percentage 8.0 % 8.3 % 8.2 % 8.2 %
 
 

Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA and related Non-GAAP Adjusted EBITDA Margin:

 
       

Three Months Ended
September 30,

      Six Months Ended
September 30,
2015       2014 2015       2014
(In thousands)
GAAP Net Income $   31,803 $   16,463 $   57,976 $   33,195
Interest expense, net 20,667 18,193 42,551 32,846
Provision for income taxes 17,428 11,862 31,425 23,280
Depreciation and amortization 5,687   3,852   11,407   6,813  
Non-GAAP EBITDA: 75,585   50,370   143,359   96,134  

Adjustments:

Inventory step-up charges and other costs associated with the Hydralyte acquisition (1) 116 246
Inventory step-up charges associated with Insight acquisition (2) 653 653
Costs associated with CEO transition (3) 1,406
Legal and professional fees associated with acquisitions (3) 8,058 9,857
Stamp/Duty Tax on Australian acquisition (3) 2,940
Integration, transition and other costs associated with acquisitions (3) 4,021 4,432
Loss on extinguishment of debt     451    
Total adjustments   12,848   1,857   18,128  
Non-GAAP Adjusted EBITDA $   75,585   $   63,218   $   145,216   $   114,262  
Non-GAAP Adjusted EBITDA Margin 36.7 % 34.9 % 36.5 % 34.9 %
 
(1) Inventory step-up charges and other costs relate to our International OTC Healthcare segment
(2) Inventory step-up charges relate to our North American OTC Healthcare segment
(3) Adjustments relate to G&A expenses
 
 

Reconciliation of GAAP Net Income to Non-GAAP Adjusted Net Income and related Adjusted Earnings Per Share:

 
        Three Months Ended September 30,       Six Months Ended September 30,
2015    

2015
Adjusted
EPS

        2014    

2014
Adjusted
EPS

2015    

2015
Adjusted
EPS

      2014    

2014
Adjusted
EPS

(In thousands)                
GAAP Net Income $   31,803       $     0.60     $   16,463       $     0.31     $   57,976       $     1.09   $   33,195       $     0.63  

Adjustments:

Inventory step-up charges and other costs associated the Hydralyte acquisition (1) 116 246
Inventory step-up charges associated with Insight acquisition (2) 653 0.01 653 0.01
Costs associated with CEO transition (3) 1,406 0.03
Legal and professional fees associated with acquisitions (3) 8,058 0.15 9,857 0.19
Stamp/Duty Tax on Australian acquisition (3) 2,940 0.06
Integration, transition and other costs associated with acquisitions (3) 4,021 0.09 4,432 0.09
Loss on extinguishment of debt 451 0.01
Tax impact of adjustments         (2,941 )     (0.06 ) (657 )     (0.01 ) (3,469 )     (0.07 )
Total adjustments         9,907       0.19   1,200       0.03   14,659       0.28  
Non-GAAP Adjusted Net Income and Adjusted EPS $   31,803       $     0.60     $   26,370       $     0.50     $   59,176       $     1.12   $   47,854       $     0.91  
                       
(1) Inventory step-up charges and other costs relate to our International OTC Healthcare segment
(2) Inventory step-up charges relate to our North American OTC Healthcare segment
(3) Adjustments relate to G&A expenses
 
 

Reconciliation of GAAP Net Income to Non-GAAP Free Cash Flow and Non-GAAP Adjusted Free Cash Flow:

 
       

Three Months Ended
September 30,

      Six Months Ended
September 30,

    2015    

     

    2014    

    2015    

     

    2014    

(In thousands)
GAAP Net Income $   31,803   $   16,463   $   57,976     $   33,195  

Adjustments:

Adjustments to reconcile net income to net cash

provided by operating activities as shown in the

Statement of Cash Flows

20,040 11,901 42,896 24,855

Changes in operating assets and liabilities, net of

effects from acquisitions as shown in the

Statement of Cash Flows

(4,774 ) (977 ) (10,282 ) (992 )
Total adjustments 15,266   10,924   32,614   23,863  
GAAP Net cash provided by operating activities 47,069 27,387 90,590 57,058
Purchases of property and equipment (903 ) (884 ) (1,683 ) (1,380 )
Non-GAAP Free Cash Flow 46,166 26,503 88,907 55,678
Integration, transition and other payments associated with acquisitions   10,018     12,417  
Adjusted Non-GAAP Free Cash Flow $   46,166   $   36,521   $   88,907   $   68,095  
       
 

Outlook for Fiscal Year 2016:

 
Reconciliation of Projected GAAP EPS to Projected Non-GAAP Adjusted EPS:

 

        2016 Projected EPS
Low         High
Projected FY'16 GAAP EPS $     2.00           $     2.05

Adjustments:

       
Costs associated with term loan refinancing and CEO transition 0.05           0.05
Total Adjustments 0.05           0.05
Projected Non-GAAP Adjusted EPS $     2.05           $     2.10
       

Reconciliation of Projected GAAP Net cash provided by operating activities to Projected Non-GAAP Free Cash Flow:

       

2016
Projected
Free Cash
Flow

(In millions)
Projected FY'16 GAAP Net cash provided by operating activities $   181
Additions to property and equipment for cash (6 )
Projected Non-GAAP Free Cash Flow $   175  
 
 

Source: Prestige Brands Holdings, Inc.

Investor & Company Contact:
Dean Siegal, 914-524-6819
dsiegal@prestigebrands.com
or
ICR
John Mills, 646-277-1254
John.mills@icrinc.com

Primary IR Contact

Irinquiries@prestigebrands.com
Prestige Consumer Healthcare Inc.
660 White Plains Road – Ste 250
Tarrytown, NY 10591
Telephone: 914-524-6819

Transfer Agent

AST
6201 15th Avenue
Brooklyn, NY 11219
Telephone: (800) 937-5449
help@astfinancial.com
https://www.astfinancial.com

Subscribe

Stay up to date with investor news, stock information and SEC filings.
Subscribe »